Market Overview - The animal health sector experienced a decline of 2.78% on January 27, with Huisheng Biological leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Stock Performance - Key stocks in the animal health sector showed varied performance, with the following notable changes: - Huisheng Biological (300871) closed at 29.89, down 8.37% with a trading volume of 376,900 shares and a transaction value of 1.148 billion [2] - Other significant declines included: - ST Lvkang (002868) down 3.86% to 35.40 [1] - Kexin Biological (688526) down 3.88% to 17.10 [1] - Haili Biological (603718) down 4.13% to 6.73 [1] Capital Flow - The animal health sector saw a net outflow of 45.7033 million from institutional investors, while retail investors experienced a net outflow of 59.3359 million [2] - Conversely, speculative funds recorded a net inflow of 105 million [2] Individual Stock Capital Flow - Notable capital flow for specific stocks included: - ST Lvkang (002868) had a net inflow of 29.8876 million from institutional investors, but a net outflow of 40.6641 million from speculative funds [3] - Zhongmu Co. (600195) saw a net inflow of 21.2767 million from institutional investors, with a significant net outflow of 66.5383 million from retail investors [3] - Jinhe Biological (002688) had a net inflow of 19.2937 million from institutional investors, but also faced a net outflow from retail investors [3]

证券代码：600201 证券简称：生物股份 公告编号：临 2026-002 金宇生物技术股份有限公司 关于股东股份质押的公告 内蒙古金宇生物控股有限公司（以下简称"生物控股"）持有金宇生物技 术股份有限公司（以下简称"本公司"、"公司"）股份 125,474,300 股， 占本公司总股本的 11.29%。本次股份质押后，其累计质押本公司股份数 量为 34,420,000 股，占生物控股持有本公司股份数量的 27.43 %。 一、公司股份质押情况 公司于 2026 年 1 月 26 日接到股东生物控股函告，获悉其将所持有的本公司 7,420,000 股无限售流通股股票质押给浙商证券股份有限公司，并办理完成了证 券质押相关手续，具体事项如下： | 股东 | 是否为 | 本次展期/ | 是否为限 | 是否补 | 质押 | | 原质押 | | 展期后到 | | 占其所 持股份 | 占公司 总股本 | 质押 融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 控股股 东 | 质 ...

Group 1 - The company, Liaoning Chengda Biological Co., Ltd., has announced a profit forecast for the year 2025, expecting a net profit attributable to shareholders of the parent company to be between 123.47 million yuan and 139.39 million yuan, representing a decrease of 59.34% to 63.98% compared to the previous year [9][10] - The company reported that the net profit for the same period last year was 403.02 million yuan, with a net profit attributable to shareholders of the parent company of 342.82 million yuan [6][9] - The decline in profit is attributed to a decrease in operating income and an increase in asset impairment losses, primarily due to changes in the domestic rabies vaccine market environment and intensified market competition [10][11] Group 2 - The company has decided to terminate the research and development project for the Hib vaccine and will fully impair the capitalized research and development costs amounting to 80.67 million yuan [36][41] - The cumulative investment in the Hib vaccine project was 161.26 million yuan, with 80.67 million yuan capitalized [38][41] - The company is in the process of establishing a biomedical investment fund with its controlling shareholder, aiming to enhance its competitiveness and capitalize on opportunities in the biopharmaceutical industry [42][48] Group 3 - The investment fund will have a total scale of no more than 1 billion yuan, with an initial scale of 502 million yuan, focusing on the life and health sector [42][48] - The fund will be jointly established by the company, its controlling shareholder, and its wholly-owned subsidiaries, with the company planning to contribute 400 million yuan as a limited partner [42][48] - The fund's investment strategy will include direct investments in high-quality projects and potential collaborations with professional management institutions [60][62]

Group 1 - The animal health sector experienced a significant increase of 5.61% on January 26, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the animal health sector showed notable price increases, with Yongshun Biological rising by 27.18% to a closing price of 11.79, and Huisheng Biological increasing by 20.01% to 32.62 [1] Group 2 - The animal health sector saw a net inflow of 437 million yuan from institutional investors, while retail investors experienced a net outflow of 307 million yuan [2] - The trading volume for Yongshun Biological reached 292,600 shares, contributing to a total transaction value of 328 million yuan [1][2] - The stock performance of various companies in the sector varied, with some experiencing significant gains while others faced declines in retail investment [3]

Group 1 - The animal vaccine concept sector rose by 4.89%, ranking fifth among concept sectors, with 18 stocks increasing in value, including Yongshun Biological, Dongfang Biological, and Haili Biological, which saw increases of 27.18%, 12.36%, and 7.18% respectively [1] - The animal vaccine sector attracted a net inflow of 229 million yuan from main funds, with 14 stocks receiving net inflows, and 5 stocks exceeding 30 million yuan in net inflow. The leading stock in net inflow was Biological Shares, with a net inflow of 100 million yuan [2] - The top three stocks by net inflow ratio were KQ Biological, Tiankang Biological, and Biological Shares, with net inflow ratios of 14.32%, 12.76%, and 9.87% respectively [3] Group 2 - The animal vaccine sector's inflow ranking included Biological Shares with a 4.50% increase and a turnover rate of 5.08%, followed by Dabeinong with a 2.70% increase and a turnover rate of 6.49% [4] - Other notable stocks included Jinhai Biological with a 5.95% increase and a turnover rate of 9.28%, and Tiankang Biological with a 1.99% increase and a turnover rate of 2.95% [5] - Stocks that experienced declines included Hengtong Holdings with a decrease of 2.59% and a turnover rate of 5.31%, and Luoniushan with a decrease of 1.86% and a turnover rate of 3.43% [5]

Group 1 - The A-share influenza vaccine sector is experiencing a strong performance, with companies such as Da'an Gene, Hualan Biological Engineering, and Zhijiang Biological reaching their daily limit up [1] - Yongshun Biological has seen an increase of over 10%, indicating positive market sentiment towards the sector [1] - Other companies in the sector, including Dongfang Biological, Biological Shares, Zhongsheng Pharmaceutical, Yiling Pharmaceutical, and Rhine Biological, are also witnessing gains [1]

Market Overview - The animal health sector experienced a decline of 0.32% on January 23, with BioShares leading the drop [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (920275) with a closing price of 9.68, up 4.09% on a trading volume of 36,300 shares and a turnover of 34.72 million yuan [1] - Haili Biological (603718) closed at 6.55, up 1.24% with a trading volume of 95,100 shares and a turnover of 61.91 million yuan [1] - Deyu Biological (920970) closed at 8.44, up 1.20% with a trading volume of 19,200 shares and a turnover of 16.26 million yuan [1] - Conversely, BioShares (600201) closed at 17.35, down 1.42% with a trading volume of 315,700 shares and a turnover of 551 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 142 million yuan from institutional investors, while retail investors experienced a net inflow of 124 million yuan [2][3] - Specific stock capital flows included: - Zhongmu Shares (600195) with a net inflow of 14.27 million yuan from institutional investors [3] - Qudongli (920275) had a net inflow of 2.44 million yuan from retail investors [3] - Deyu Biological (920970) faced a net outflow of 1.04 million yuan from institutional investors [3]

Core Viewpoint - The animal health sector experienced a slight increase of 0.54% on January 22, with Xianfeng Holdings leading the gains. The Shanghai Composite Index rose by 0.14% to close at 4122.58, while the Shenzhen Component Index increased by 0.5% to 14327.05 [1]. Group 1: Stock Performance - Xianfeng Holdings (002141) closed at 4.19, up 9.97% with a trading volume of 720,300 shares and a transaction value of 297 million yuan [1]. - Other notable performers include Biological Shares (600201) at 17.60, up 1.79%, and Zhongmu Shares (600195) at 8.54, also up 1.79% [1]. - The overall trading volume and transaction values for various stocks in the animal health sector indicate active market participation [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 73.79 million yuan from institutional investors, while retail investors experienced a net outflow of 27.83 million yuan [2]. - The main capital inflow was primarily directed towards Xianfeng Holdings, which attracted 121 million yuan from institutional investors, representing 40.71% of its trading volume [3]. - Other stocks like Jinhe Biological (002688) and *ST Green Health (002868) also saw varying degrees of net inflow and outflow from different investor categories [3].

Core Viewpoint - The animal health sector experienced a decline of 0.65% on January 21, with Huisheng Biological leading the drop. The Shanghai Composite Index rose by 0.08%, while the Shenzhen Component Index increased by 0.7 [1] Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Shunlian Biological up by 4.20% and Huisheng Biological down by 6.19% [1][2] - The trading volume for Huisheng Biological was 419,900 shares, with a transaction value of 1.192 billion yuan, indicating significant market activity despite the decline [2] Group 2: Capital Flow - The animal health sector saw a net inflow of 9.6935 million yuan from institutional investors, while retail investors experienced a net outflow of 73.8174 million yuan, suggesting a shift in investor sentiment [2][3] - Among individual stocks, Xianfeng Holdings had a net inflow of 15.1182 million yuan from institutional investors, while Huisheng Biological saw a net outflow of 42.2249 million yuan from retail investors [3]

Core Viewpoint - The major shareholder of Baolingbao Bio-Pharmaceutical Co., Ltd., Ningbo Baopu Futong Asset Management Center (Limited Partnership), has completed its share reduction plan, selling a total of 11,416,905 shares, which represents approximately 3% of the company's total share capital [2][3]. Group 1: Share Reduction Plan - The shareholder, Baopu Futong, initially held 27,046,297 shares, accounting for 7.10684% of the total share capital, and planned to reduce its holdings by up to 11,417,020 shares within a specified period [2]. - The reduction was executed through both centralized bidding and block trading, with a maximum of 2% (7,611,347 shares) allowed to be sold via block trading and 1% (3,805,673 shares) via centralized bidding within any consecutive 90-day period [2][3]. Group 2: Share Reduction Details - The shares were acquired through a private transfer in December 2016, with the selling price ranging from 11.31 to 11.45 CNY per share for centralized bidding and from 8.64 to 8.66 CNY per share for block trading [3]. - The implementation of the reduction plan was in compliance with relevant laws and regulations, ensuring that it did not affect the company's control structure or governance [4][5].